from a societal perspective
Russian translation: как издержки для общества
| GLOSSARY ENTRY (DERIVED FROM QUESTION BELOW) | ||||||
|---|---|---|---|---|---|---|
|
| 13:47 Nov 30, 2017 |
| English to Russian translations [PRO] Science - Economics | |||||||
|---|---|---|---|---|---|---|---|
|
| ||||||
|  Selected response from: Lazyt3ch Local time: 13:06 | ||||||
Grading comment
| |||||||
| Summary of answers provided | ||||
|---|---|---|---|---|
| 3 | с общественной точки зрения |
| ||
| 3 | как издержки для общества |
| ||
| 2 +1 | с позиции общества |
|
| Summary of reference entries provided | |||
|---|---|---|---|
| принимая во внимание социальные факторы (положения, состояние, обстоятельства) |
|
| Discussion entries: 5 | |
|---|---|
Answers
3 hrs confidence: 
с общественной точки зрения Explanation: deplorable vagueness of the original. |
| |
| Login to enter a peer comment (or grade) | ||
56 mins confidence:
как издержки для общества Explanation: Затраты были подсчитаны как издержки для общества -------------------------------------------------- Note added at 12 hrs (2017-12-01 01:55:28 GMT) -------------------------------------------------- Статьи в тему: Costing and perspective in published cost-effectiveness analysis. - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/19536023 == BEGIN QUOTE == RESULTS: In practice, there has been a great deal of variation in costing methodology used in published CEAs, though methods have improved somewhat over time. Many CE researchers continue to claim that their studies take a societal perspective, but instead their articles only consider a health care payer perspective. == END QUOTE == Ten arguments for a societal perspective in the economic evaluation of medical innovations | SpringerLink https://link.springer.com/article/10.1007/s10198-009-0173-2 == BEGIN QUOTE == Health technology assessment (HTA) is increasingly used to assist decisions about reimbursement and funding of new medical technologies, particularly drugs. This means that the economic evaluation that is part of an HTA will form the core element of an assessment used for guiding decisions on resource allocation. While HTA in general has a societal policy perspective, many HTA and reimbursement agencies advising payers take a narrow budget perspective on the impact on resource use when performing economic evaluations. Examples of such agencies are the National Institute for Health and Clinical Excellence (NICE) in England and Wales, the Canadian Agency for Drugs and Technologies in Health (CADTH) in Canada, the Pharmaceutical Management Agency (Pharmac) in New Zealand, and the reimbursement agency NIHISB in Belgium. A number of initiatives for introducing or promoting the use of use HTA for health care policy making (IQWIG, EUnetHTA) seem uncertain about where to stand on the perspective of economic evaluation. There is also an important discussion about the consequences for pharmaceutical innovation of using cost-effectiveness studies to determine which technologies should qualify for reimbursement [1]. Ignoring important costs and benefits in an economic evaluation will lead to an inefficient allocation of resources, in the short term as well as from a long-term perspective. Cost-effective drugs will not be reimbursed and incentives for innovation will be adversely affected. The role of HTA in establishing a transparent and efficient global market for medical innovations may therefore be questioned. This paper provide ten arguments for taking a broad societal perspective on value, specifically to include all relevant costs, in HTA studies aimed at informing decisions about resource allocation. The purpose is to advocate that a broad perspective on value is necessary in order for the study to provide the correct incentives for decision makers to take into account, for both static and dynamic efficiency, when making decisions about allocation of resources for improvement of health. For a more in depth discussion, see [2]. == END QUOTE == (подчеркивание везде мое) Как нетрудно заметить, societal perspective в первой статье противопоставляется health care payer perspective, а во второй — budget perspective. |
| |
| Login to enter a peer comment (or grade) | ||
21 hrs confidence: peer agreement (net): +1
peer agreement (net): +1с позиции общества Explanation: "Анализ проводили с позиции системы здравоохранения (учет только прямых медицинских затрат) и с позиции общества в целом (учет прямых медицинских и непрямых затрат)", - journal.niidi.ru/jofin/article/download/241/239 "Perspective in pharmacoeconomics refers to the economic vantage point of a pharmacoeconomic analysis, such as a cost-effectiveness analysis or cost-utility analysis... Five general perspectives are often cited in pharmacoeconomics, including institutional, third party, patient, governmental and societal....", - https://en.wikipedia.org/wiki/Perspective_(pharmacoeconomic) Ещё примеры: - "...Позиция исследования: точка зрения, с которой происходит оценка затрат и результатов в исследовании... ...определите потенциальные затраты и выгоды. С позиции общества в целом, пациента, учреждения, плательщика, врача могут существенно меняться выводы...", - http://www.myshared.ru/slide/635626/ (П. А.Воробьев. Президент Общества фармакоэкономических исследований RSPOR...) - "...проведение клинико-экономического анализа с позиции общества или системы здравоохранения", - http://clinvest.ru/news/item/rol-farmakoekonomicheskogo-anal... Другие всречающиеся варианты: - общественные расходы - https://cyberleninka.ru/article/n/kliniko-ekonomicheskie-pod... - экономическая составляющая по отношению к обществу - http://clinical-pharmacy.ru/article/28-tipy-i-metody-provede... |
| |
| Login to enter a peer comment (or grade) | ||
Reference comments
14 hrs |
| Reference: принимая во внимание социальные факторы (положения, состояние, обстоятельства) Reference information: 1. принимая внимания социальные факторы (положения, состояние, обстоятельства, регион проживания пациентов) или стоимость лечения зависит от этих факторов 2. Второй вариант не очень подходит потому что здесь идет речь стоимости лечения определенных ран/язв: принимая внимания социальной стоимости, социальной значимости этих "социально значимых заболеваний" Или с точки зрения социальных факторов https://www.google.com/search?q=%D1%84%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B+%D0%B2%D0%BB%D0%B8%D1%8F%D1%8E%D1%89%D0%B8%D0%B5+%D0%BD%D0%B0+%D1 |
| |
| Login to enter a peer comment (or grade) | ||
Login or register (free and only takes a few minutes) to participate in this question.
You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.
KudoZ™ translation help
The KudoZ network provides a framework for translators and others to assist each other with translations or explanations of terms and short phrases.
See also:
Search millions of term translations